EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Evidence-Based Medicine 2005;10:139; doi:10.1136/ebm.10.5.139
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lang, E. S
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lang, E. S

Therapeutics

ED use of magnesium sulphate improved rate control in atrial fibrillation with rapid ventricular response

Davey MJ, Teubner D. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation. Ann Emerg Med 2005;45:347–53.[CrossRef][Medline]

Q In emergency department (ED) patients with atrial fibrillation (AF) and a rapid ventricular response rate, what is the efficacy and safety of magnesium sulphate administered within the first 2.5 hours in addition to usual care?

Clinical impact ratings IM/Ambulatory care ******{star} Emergency medicine ******{star} Cardiology ******{star}

Key Words: atrial fibrillation • antiarrhythmia agents • magnesium sulphate

The first 150 words of the full text of this article appear below.

METHODS
{ebmflochart.f1}Design: randomised controlled trial (RCT).

{ebmclsdenvelop.f1}Allocation: {concealed*}{dagger}.

{ebmhalfeye.f1}Blinding: blinded (patients, clinicians, {data collectors, outcome assessors, monitoring committee}{dagger}, and data analysts).*

{ebmhourglass.f1}Follow up period: up to 150 minutes.

{ebmglobe.f1}Setting: 2 academic, tertiary referral EDs in South Australia.

{ebmpatient.f1}Patients: 199 patients (approximately 52% women) >18 years of age who presented to the ED with AF and a ventricular response rate >120 beats/min. Exclusion criteria were haemodynamic instability, history of renal failure or atrioventricular node disease (except for patients with primary atrioventricular block or permanent pacemakers), or acute myocardial infarction with electrocardiographic criteria for thrombolysis.

{ebmrx.f1}Intervention: magnesium sulphate, 40 mEq (5 g, 20 mmol), in 100 ml 5% dextrose solution, with 20 mEq (2.5 g, 10 mmol) given intravenously over 20 minutes, followed by the remaining 20 mEq over the next 2 hours (n = 102); or an equivalent volume of 5% dextrose solution at the same infusion rates (placebo) . . . [Full text of this article]

Eddy S Lang, MDCM, CCFP(EM), CSPQ

SMBD Jewish General Hospital, McGill University
Montreal, Quebec, Canada







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.